Gautam Patel Sells 80,000 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $8.14, for a total transaction of $651,200.00. Following the completion of the transaction, the director now directly owns 1,888,886 shares of the company’s stock, valued at approximately $15,375,532.04. This represents a 4.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Gautam Patel also recently made the following trade(s):

• On Wednesday, January 8th, Gautam Patel sold 62,590 shares of Amneal Pharmaceuticals stock. The stock was sold at an average price of $8.01, for a total transaction of $501,345.90.
• On Thursday, January 2nd, Gautam Patel sold 17,410 shares of Amneal Pharmaceuticals stock. The shares were sold at an average price of $8.01, for a total value of $139,454.10.

Amneal Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ AMRX opened at $7.85 on Friday. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $9.48. The firm’s 50-day simple moving average is $8.14 and its 200 day simple moving average is $8.23. The stock has a market cap of $2.43 billion, a P/E ratio of -11.54 and a beta of 1.10.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Gladius Capital Management LP bought a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at about $37,000. Quest Partners LLC bought a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at about $84,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter valued at about $81,000. Janney Montgomery Scott LLC bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter valued at about $121,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at about $169,000. 31.82% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on AMRX. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Piper Sandler raised their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.